A new immunotherapy can greatly extend the lives of a proportion of people with advanced head and neck cancer, with some living for three years or more, a major new clinical trial reports.
Dec 1, 2018
1
67
Data from the newly established UK skin cancer database, the largest database of its kind in the world, has revealed that there are over 45,000 cutaneous squamous cell carcinomas (cSCC) every year in England, 350 per cent ...
Nov 28, 2018
0
10
Loss of a protein called TRIM29 promotes cancer cell invasion in a common type of skin cancer, suggesting a novel diagnostic marker and a possible therapeutic target.
Nov 21, 2018
0
2
A new method of using a Scottish company's portable microwave technology to treat sun-damaged skin conditions is being tested by researchers at the University of Dundee.
Nov 9, 2018
0
1
Delayed care is a crtically important factor in the survival of patients with head and neck cancer, and the patients who most often experience these delays are African American, according to two new studies at the Medical ...
Nov 6, 2018
0
1
A new blood test developed by University of North Carolina Lineberger Comprehensive Cancer Center researchers shows promise for tracking HPV-linked head and neck cancer patients to ensure they remain cancer-free after treatment.
Oct 23, 2018
0
0
By combining data on individuals' lifetime sun exposure and their genetics, researchers can generate improved predictions of their risk of skin cancer, according to findings presented at the American Society of Human Genetics ...
Oct 17, 2018
0
1
Squamous cell carcinomas (SCCs) are aggressive malignancies arising from the squamous epithelium of various organs, such as the esophagus, head and neck, lungs, and skin. Previous studies have demonstrated that two master ...
Oct 16, 2018
0
21
Patients with metastatic NSCLC receiving treatment at academic centers (ACs) have an increased 2-year survival compared to patients treated at community-based centers (CCs). An overall histology-dependent survival was also ...
Oct 10, 2018
0
1
(HealthDay)—Libtayo (cemiplimab-rwlc) injection has been approved by the U.S. Food and Drug Administration to treat advanced squamous cell carcinoma (CSCC), the agency said in a news release.
Oct 1, 2018
0
1
